BioCentury
ARTICLE | Company News

Japan approvals include Hemlibra, Shingrix, Galafold

March 23, 2018 10:09 PM UTC

Japan approved a basket of drugs including hemophilia drug Hemlibra emicizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), shingles vaccine Shingrix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Fabry's disease drug Galafold migalastat from Amicus Therapeutics Inc. (NASDAQ:FOLD).

Japan's Ministry of Health, Labour and Welfare (MHLW) approved Hemlibra to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A with Factor VIII inhibitors. Chugai, which is majority owned by Roche (SIX:ROG; OTCQX:RHHBY), initially developed Hemlibra and Roche opted into development of the product in 2014. The bispecific mAb that binds Factor IXa and Factor X is also approved in the U.S. and EU...